Lotte Biologics wins Alvotech biosimilar work for its Syracuse plant

The capital in this deal sits with Lotte. Its Syracuse plant has 40,000 liters of bioreactor capacity plus in-house process development and quality control ^[8]. Alvotech is adding the site to its own development and manufacturing and to the capacity of its existing partners ^[9]. Alvotech buys US output through a contract, and the plant and its fixed costs stay with Lotte.

"With the expansion of our global manufacturing network, we will have sufficient capacity to meet demand for our pipeline for the next ten years," Lisa Graver, Alvotech's chief executive, said ^[5]. A client that says ten years of demand is covered has largely finished shopping for capacity. Or rather, the version that matters to Lotte: more Alvotech work depends on how many Alvotech products get approved and sell. Graver's sentence puts the pace of growth on Alvotech's launch calendar, even as Lotte says the two companies plan to expand the collaboration ^[11].

Alvotech did stress the location. Graver said the deal "will bring additional manufacturing capacity in New York to support patients worldwide" ^[6], and the drug substance is for supply to global markets ^[1]. Neither company's statement links the agreement to US tariffs or onshoring rules. One contract is also too small a sample to say Korean contract manufacturers as a group are taking US share.

Lotte's own pitch points partly away from a US-site story. "With our Syracuse operations and the completion of our Songdo Bio Campus, we are committed to providing flexible, dual-site manufacturing support as the partnership grows," James Park, Lotte's co-CEO, said ^[7]. Lotte plans to link Syracuse and Songdo closely enough to meet client demand across global supply chains ^[4]. Under that design, growth in an account opened in New York can be produced in Korea.

If the undisclosed products turn out to be high-volume, they fill a meaningful share of Syracuse and the US-share reading holds. A slow technology transfer, qualification or regulatory review, all required before commercial supply ^[13], would leave Lotte holding a signed contract with little commercial output for some time. The third path sends the next tranche to Songdo, with Syracuse as the site that won the client. I think the third is what Lotte is selling. Syracuse won the account on US credentials: an unannounced FDA inspection that, according to Lotte, ended with zero observations ^[3], and a record of commercial manufacturing at the site ^[10]. Park's dual-site language describes where the growth would go. That view is wrong if Alvotech's next expansion with Lotte is booked in Syracuse instead of Songdo.